The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BioInvent International AB's Revenue for the
three
months ended in Mar. 2026 was $1.44 Mil. BioInvent International AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was $2.12 Mil.
Hence, BioInvent International AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.68.
BioInvent International AB (OTCPK:BOVNF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BioInvent International AB Receivables Turnover Related Terms
BioInvent International AB Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB Receivables Turnover Chart
BOVNF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, BioInvent International AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB (BOVNF) has a Receivables Turnover of 0.68 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioInvent International AB and its competitors. According to the industry distribution chart, BioInvent International AB ranks #459 out of 841 companies in the Biotechnology industry, placing it in the top 54.6%.
Is BioInvent International AB's Receivables Turnover too high?
BioInvent International AB's current Receivables Turnover is 0.68. The Biotechnology industry median Receivables Turnover is 5.29. BioInvent International AB's value of 0.68 is 87.1% below this industry median. Based on the distribution chart, BioInvent International AB ranks #459 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioInvent International AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #459 out of 841 companies for Receivables Turnover. This places BioInvent International AB in the lower half of its industry. The industry median Receivables Turnover is 5.29. BioInvent International AB's value of 0.68 is 87.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioInvent International AB's current Receivables Turnover of 0.68 is 87.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioInvent International AB and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioInvent International AB's current Receivables Turnover is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current Receivables Turnover of 0.68. The stock's GF Value™ is $7.07, compared to a current price of $3.29 — trading 53.5% below its estimated fair value. The current Receivables Turnover is 0.68 and 87.1% below the Biotechnology industry median of 5.29. BioInvent International AB's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current Receivables Turnover is 0.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (BOVNF) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of $3.29 is trading 53.5% below its estimated GF Value™ of $7.07.
Key valuation signals for BOVNF:
Receivables Turnover: 0.68
GF Value™: $7.07 vs. price of $3.29 (53.5% below fair value)
Industry Position: 87.1% below the Biotechnology median (#459 of 841)
No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
39GF Score
Get the complete analysis for BOVNF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOVNF has been successfully added to your 
